Heidi’s Law directs the Secretary of Health and Human Services to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs to add methadone to the opiate testing category within 90 days of enactment and requires publication of a final Federal Register notice. The bill then requires the Secretary of Transportation to amend DOT drug- and alcohol-testing regulations to include methadone within 60 days after HHS publishes that notice.
Beyond the immediate methadone insertion, the bill compels HHS to perform an annual review and, when appropriate, expand the list of substances authorized for federal workplace testing; DOT must follow each annual HHS update by revising its testing regulations within 60 days. The measure thus creates recurring, binding update obligations for two agencies with tight implementation windows, affecting federal employers, DOT-regulated workplaces, testing laboratories, and employees who use methadone as medication-assisted treatment (MAT).
At a Glance
What It Does
The bill requires HHS to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs to include methadone in the opiate category and publish the change within 90 days. It then requires DOT to update its transportation employee drug-testing panels to include methadone within 60 days of the HHS notice and repeats that process annually for newly identified substances.
Who It Affects
Federal employers and any workplace that follows the HHS Mandatory Guidelines, Department of Transportation-regulated employers and safety-sensitive transportation employees (e.g., pilots, truck drivers, transit operators), and federally certified testing laboratories that must add/validate methadone assays. Medication-assisted treatment providers and patients who take prescribed methadone are directly implicated because presence will now be explicitly tested in these programs.
Why It Matters
The bill alters what substances federal and DOT testing programs must detect and binds agencies to short regulatory timelines, forcing rapid operational changes—updating lab procedures, employer policies, and compliance systems. It also raises clinical and legal questions because methadone is a prescribed medication for opioid use disorder; adding it to testing panels changes the information employers receive without providing new guidance on interpretation or accommodation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Heidi’s Law inserts methadone into the scope of federally authorized workplace drug testing by directing HHS to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs so that the opiate category explicitly includes methadone. The bill sets a firm 90-day deadline for HHS to complete and publish that revision in the Federal Register.
Once HHS publishes the final notice, DOT has 60 days to change any of its regulations that govern transportation employee drug and alcohol testing to mirror HHS’s change.
The bill does more than a one-time insertion. It obligates HHS to conduct an annual review of the Mandatory Guidelines and, if the Secretary determines additional drugs should be added, to revise the authorized testing list and publish a final notice.
For each such HHS notice, DOT must again move within 60 days to update its transportation testing regulations so that DOT panels remain consistent with the federal Mandatory Guidelines.Practically speaking, the law creates two linked operational flows: (1) a rapid initial insertion of methadone into the federal testing universe, and (2) a recurring annual pipeline for adding newly identified substances. That produces predictable duties for HHS (review and revision; Federal Register publication), for DOT (regulatory updates within 60 days of HHS notices), and for testing laboratories and employers (validating assays, amending testing panels, and updating policies and contracts).
The statute does not itself set testing cutoffs, confirmatory methods, adjudication procedures, or accommodation rules; it relies on the existing Mandatory Guidelines and DOT rulemaking to fill those details.
The Five Things You Need to Know
The Secretary of Health and Human Services must revise the Mandatory Guidelines to include methadone within 90 days of enactment and publish a final Federal Register notice.
Within 60 days after HHS publishes that notice, the Secretary of Transportation must amend DOT regulations to include methadone on transportation employee drug-testing panels.
HHS must perform an annual review and, if appropriate, revise the Authorized Substances list in the Mandatory Guidelines to add newly identified drugs that the Secretary believes should be included.
For each annual HHS revision, DOT has 60 days after HHS’s final notice to update its transportation testing regulations to match the Mandatory Guidelines.
The bill instructs both agencies to act on fixed, short timelines but does not specify analytical cutoffs, confirmatory testing protocols, exemptions, or employment-adjudication procedures for positive methadone results.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Add methadone to HHS Mandatory Guidelines and publish notice
This provision directs HHS to modify the Mandatory Guidelines for Federal Workplace Drug Testing Programs to expand the opiate category to include methadone and to issue a final Federal Register notice after completing the revision. The practical effect is that federal workplace testing that follows these Guidelines will be authorized—and thus expected—to detect methadone; the provision imposes a 90-day deadline on HHS, compressing the typical time HHS uses for updates and notice-and-comment work.
Force DOT to incorporate methadone into transportation testing
Once HHS publishes its final notice, DOT must update any regulations governing transportation employee drug-testing programs to include methadone within 60 days. The section ties DOT’s testing panels directly to HHS’s Mandatory Guidelines, making DOT’s timelines dependent on HHS’s actions and effectively synchronizing federal workplace and transportation testing panels for methadone detection.
Annual HHS review to add newly identified drugs
This section requires HHS to conduct an annual review of the Mandatory Guidelines and to revise the authorized testing list when the Secretary concludes additional substances should be added; HHS must publish any such revisions in the Federal Register. That establishes a recurring statutory duty—not left to HHS discretion—to consider and, when deemed appropriate, expand testing authorization on a yearly cadence.
Annual DOT updates to match HHS additions
Mirroring Section 3, Section 5 requires DOT to update transportation employee testing regulations within 60 days after any HHS final notice under the annual review. This creates a standing procedure: HHS adds substances via the Mandatory Guidelines; DOT must promptly align its panels with those changes, creating predictable regulatory churn for DOT-regulated employers and labs.
This bill is one of many.
Codify tracks hundreds of bills on Employment across all five countries.
Explore Employment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- DOT and transportation safety regulators — the bill provides a statutory route to ensure transportation testing panels explicitly detect methadone, which regulators can argue improves oversight of safety-sensitive workers.
- Federal agencies that follow the HHS Mandatory Guidelines — these employers gain a clear, uniform rule authorizing methadone testing across federal workplace programs.
- Forensic and clinical toxicology laboratories — mandated additions create demand for validated methadone assays, confirmation testing, and expanded laboratory services and contracts.
- Occupational safety and compliance vendors — companies that provide testing program administration, policy templates, and compliance software will secure new work to update programs and train personnel.
Who Bears the Cost
- DOT-regulated employees on prescribed methadone — employees using methadone for opioid use disorder or chronic pain face increased risk of detection in workplace panels, with potential employment consequences absent accommodation rules.
- Employers and transit agencies — they must update drug-testing policies, revise employee handbooks, renegotiate lab contracts, and absorb testing and administrative costs tied to adding methadone to panels.
- Testing laboratories — labs must validate methadone screening and confirmatory assays, adjust workflows, and possibly add instrumentation or staff training, which imposes start-up costs.
- HHS and DOT administrative resources — both agencies face compressed timelines (90 and 60 days) and a recurring annual review/updating duty that will require rule drafting, coordination, and Federal Register publications, potentially diverting staff from other work.
Key Issues
The Core Tension
The bill attempts to strengthen workplace and transportation safety by expanding what drug tests detect, but it does so by prioritizing detection over contextual medical judgment: finding methadone in a specimen does not equal impairment, and mandatory detection without defined interpretive rules forces employers and agencies to choose between protecting safety and potentially penalizing lawful, clinically supervised treatment.
The bill mandates the detection of methadone but says nothing about how positive results should be interpreted, how to distinguish lawful prescription use from misuse, or whether detection alone can justify employment sanctions. Methadone is commonly prescribed as medication-assisted treatment for opioid use disorder and as a pain medication; presence in a test does not measure impairment.
Without accompanying procedural protections—medical review officer standards tailored to methadone, defined cutoffs that reduce false positives, exemptive rules for prescribed use, or guidance on reasonable accommodation—the change may produce false inferences about fitness for duty.
Operationally, the short deadlines (90 days for HHS, 60 days for DOT) create implementation risk. HHS must produce an authoritative revision to the Mandatory Guidelines and publish a final notice quickly; DOT must then finish potentially complex rule changes on a 60-day clock.
Testing labs need time to validate assays and implement confirmatory testing practices; regulatory compression increases the chance of rollout errors or uneven enforcement. The annual review requirement is likewise blunt: requiring HHS to consider and potentially add substances each year can be a useful safety mechanism, but it also exposes the process to recurring administrative churn and the prospect that politically driven additions (or omissions) could occur without a transparent, science-driven framework specified in the statute.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.